Who are Salmeterol 50 mcg via DISKUS's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/salmeterol-50-mcg-via-diskus.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Salmeterol 50 mcg via DISKUS — Competitive Intelligence Brief

Salmeterol 50 mcg via DISKUS (Salmeterol 50 mcg via DISKUS) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting beta2-adrenergic agonist (LABA). Area: Respiratory.

marketed Long-acting beta2-adrenergic agonist (LABA) Beta2-adrenergic receptors Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Salmeterol 50 mcg via DISKUS (Salmeterol 50 mcg via DISKUS) — GlaxoSmithKline. Salmeterol is a long-acting beta2-adrenergic agonist that relaxes bronchial smooth muscle to improve airflow.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Salmeterol 50 mcg via DISKUS TARGET	Salmeterol 50 mcg via DISKUS	GlaxoSmithKline	marketed	Long-acting beta2-adrenergic agonist (LABA)	Beta2-adrenergic receptors
Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI	Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI	Orion Corporation, Orion Pharma	marketed	Combination of inhaled corticosteroid (ICS) and long-acting beta2-adrenergic agonist (LABA)	Glucocorticoid receptors and β2-adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting beta2-adrenergic agonist (LABA) class)

GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Salmeterol 50 mcg via DISKUS — Competitive Intelligence Brief. https://druglandscape.com/ci/salmeterol-50-mcg-via-diskus. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab